Last reviewed · How we verify
Shenyankangfu tablets and Losartan potassium 50mg
Shenyankangfu tablets and Losartan potassium 50mg is a Small molecule drug developed by Chinese PLA General Hospital. It is currently FDA-approved.
At a glance
| Generic name | Shenyankangfu tablets and Losartan potassium 50mg |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shenyankangfu tablets and Losartan potassium 50mg CI brief — competitive landscape report
- Shenyankangfu tablets and Losartan potassium 50mg updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI
Frequently asked questions about Shenyankangfu tablets and Losartan potassium 50mg
What is Shenyankangfu tablets and Losartan potassium 50mg?
Shenyankangfu tablets and Losartan potassium 50mg is a Small molecule drug developed by Chinese PLA General Hospital.
Who makes Shenyankangfu tablets and Losartan potassium 50mg?
Shenyankangfu tablets and Losartan potassium 50mg is developed and marketed by Chinese PLA General Hospital (see full Chinese PLA General Hospital pipeline at /company/chinese-pla-general-hospital).
What development phase is Shenyankangfu tablets and Losartan potassium 50mg in?
Shenyankangfu tablets and Losartan potassium 50mg is FDA-approved (marketed).